EPI-7386 is intended for the treatment of prostate cancer. Credit: Nephron/commons.wikimedia.org.

ESSA Pharma has signed a clinical trial support agreement with Janssen Research & Development to evaluate its EPI-7386 combinations for the treatment of men with prostate cancer.

As per the agreement, Janssen will supply ESSA with apalutamide and abiraterone acetate for a Phase I clinical trial which will be sponsored and conducted by the latter.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumour activity of EPI-7386 when administered in combination with either apalutamide or abiraterone acetate plus prednisone.

Patients with metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC) will receive EPI-7386 along with abiraterone acetate plus prednisone in Cohort A of the Phase I trial.

In Cohort B, a window of opportunity study, non-metastatic CRPC patients will be dosed with single agent EPI-7386 before adding standard-of-care apalutamide for up to 12 weeks.

See Also:

ESSA president and CEO David Parkinson said: “We are pleased to have this agreement in place in order to further investigate EPI-7386 in combination with apalutamide and abiraterone acetate plus prednisone in a variety of prostate cancer patient populations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Preliminary clinical data from EPI-7386 combination studies with standard-of-care antiandrogens in mCRPC patients have shown a favorable safety profile and encouraging early signs of anti-tumour activity.

“We look forward to examining EPI-7386 with apalutamide and abiraterone acetate with prednisone in additional prostate cancer populations to assess the safety, tolerability, optimal dose(s) and preliminary anti-tumour activities of these approaches.”

Across the globe, ESSA will retain all rights to the oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, EPI-7386.

The company is also evaluating EPI-7386 in combination with enzalutamide in a Phase I/II trial in metastatic CRPC patients who are yet to receive treatment with second-generation antiandrogen therapies.